Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study

André, Thierry; Tournigand, Christophe; Mineur, Laurent; Fellague-Chebra, Rafik; Flesch, M.; Mabro, May; Hebbar, Mohamed; Vinay, S. P.; Bidard, François-Clément; Louvet, Christophe; Gramont, Aimery de

doi:10.1093/annonc/mdl336

Cited by 41 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This strategy was carried on with the introduction of doublets. However this strategy has to be revised as recent studies have shown that an intermittent strategy compared with continuous use of chemotherapy does not compromise efficacy 19,20…”

Section: Duration Of Combination Chemotherapymentioning

confidence: 99%

“…The overall conclusion of OPTIMOX1 and OPTIMOX2 was that a total pause in treatment can not be recommended after only 3 months of treatment due to an inferior OS 19,21. However single-drug treatment or biological treatment may be used as maintenance therapy 19,21.…”

Section: Duration Of Combination Chemotherapymentioning

confidence: 99%

“…However single-drug treatment or biological treatment may be used as maintenance therapy 19,21. A new analysis of these data showed that a treatment pause is fully acceptable if therapy is given for at least 6 months 22…”

Section: Duration Of Combination Chemotherapymentioning

confidence: 99%

See 2 more Smart Citations

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

Pfeiffer¹,

Qvortrup²,

Bjerregaard³

2008

OTT

View full text Add to dashboard Cite

Purpose: Elderly cancer patients often have co-morbidities and other characteristics that make the selection of optimal treatment more complex. The introduction of targeted therapies in colorectal cancer has further complicated this problem. This review will focus on the role of the EGFR antibody cetuximab in elderly patients. Methods: We have reviewed the available evidence in the literature to evaluate the results of therapy with cetuximab, alone or in combination with chemotherapy, with a focus on elderly patients with metastatic colorectal cancer (mCRC). Results: In patients with mCRC, combination chemotherapy prolongs median survival to more than 18 months and even around 24 months in combination with cetuximab in selected patients. No prospective studies have evaluated cetuximab in elderly patients. However, subgroup analyses from randomized trials and retrospective analysis suggest that the effi cacy of chemotherapy and cetuximab is maintained in fi t elderly patients, but with slightly increased but acceptable toxicity. Conclusion:No prospective cetuximab studies have been conducted solely in a population of elderly patients. However, available data suggest that outcomes in the fi t elderly mirror results observed in younger patients.

show abstract

Section: Duration Of Combination Chemotherapymentioning

confidence: 99%

Section: Duration Of Combination Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

Pfeiffer¹,

Qvortrup²,

Bjerregaard³

2008

OTT

View full text Add to dashboard Cite

show abstract

“…However, the potential interest of this treatment has been challenged by the fact that in the preliminary results of a recent trial comparing patients treated with FOLFOX and chelators in contrast with FOLFOX alone, the response rate was lower in patients receiving the neuroprotective agents [13 ]. Nonpharmacological attempts to reduce toxicity could also be valuable alternatives and several authors [21][22][23] advocate a 'stop and go' scheme alternating oxaliplatin-based chemotherapy with another drug or combination.…”

Section: Platinum Compoundsmentioning

confidence: 99%

Neuropathies in the context of malignancies

Béhin

Psimaras

Hoang-Xuân

et al. 2008

Current Opinion in Neurology

View full text Add to dashboard Cite

show abstract

“…Although considerable progress has been made in the treatment of patients with CRC, half of all patients will eventually develop metastatic CRC (mCRC). Median survival was extended from barely six months without treatment to one year using folinic acid (FA)-modulated 5-fluorouracil , and with the incorporation of new chemotherapeutic agents (e.g., oxaliplatin and irinotecan) to over 20 months [2]. The combination of newly approved biological agents, such as bevacizumab and cetuximab, promises to prolong survival still more [3,4].…”

mentioning

confidence: 99%

Molecular markers in colorectal cancer: genetic bases for a customised treatment

et al. 2007

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second leading cause of cancer death in Western countries. CRC treatment is based on the employment of three chemotherapeutic drugs, including 5-fluorouracil, oxaliplatin and irinotecan, and the use of recently incorporated targeted agents directed to vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). The approval of these biologicals and of others to come holds great promise for the improvement of patient outcome. The molecular bases for this lethal disease have been extensively investigated, laying the foundations for a rational and customised treatment approach, expanding the therapeutic index of current drugs and easing the incorporation of new molecules. Individual markers have been mainly investigated based on drug targets and metabolism. Also, the increasing availability of highthroughput technologies has prompted the opportunity for blind studies capable of screening new markers and of identifying the specific oncogenic pathways responsible for drug resistance in a given patient. An updated review of the field is presented in this article.

show abstract

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study

Cited by 41 publications

References 14 publications

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

Neuropathies in the context of malignancies

Molecular markers in colorectal cancer: genetic bases for a customised treatment

Contact Info

Product

Resources

About